These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20345884)

  • 61. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
    Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
    J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
    Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
    AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
    Sanne I; Piliero P; Squires K; Thiry A; Schnittman S;
    J Acquir Immune Defic Syndr; 2003 Jan; 32(1):18-29. PubMed ID: 12514410
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.
    Vora S; Marcelin AG; Günthard HF; Flandre P; Hirsch HH; Masquelier B; Zinkernagel A; Peytavin G; Calvez V; Perrin L; Yerly S;
    AIDS; 2006 Jan; 20(1):35-40. PubMed ID: 16327317
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
    Santoro MM; Bertoli A; Lorenzini P; Ceccherini-Silberstein F; Gianotti N; Mussini C; Torti C; Di Perri G; Barbarini G; Bini T; Melzi S; Caramello P; Maserati R; Narciso P; Micheli V; Antinori A; Perno CF;
    Infection; 2009 Jun; 37(3):233-43. PubMed ID: 19169632
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
    Monforte Ad; Reiss P; Ryom L; El-Sadr W; Dabis F; De Wit S; Worm SW; Law MG; Weber R; Kirk O; Pradier C; Phillips AN; Lundgren JD; Sabin CA
    AIDS; 2013 Jan; 27(3):407-15. PubMed ID: 23291539
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
    Hill A
    AIDS; 2005 Nov; 19(17):2054-5. PubMed ID: 16260922
    [No Abstract]   [Full Text] [Related]  

  • 68. Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.
    Viglietti D; Verine J; De Castro N; Scemla A; Daudon M; Glotz D; Pillebout E
    Antivir Ther; 2011; 16(1):119-21. PubMed ID: 21311116
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.
    Wang Q; Young J; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Furrer H; Fehr J; Bucher HC; Battegay M;
    HIV Clin Trials; 2014; 15(3):92-103. PubMed ID: 24947533
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
    Hamada Y; Nishijima T; Komatsu H; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    PLoS One; 2013; 8(7):e69845. PubMed ID: 23875004
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.
    Flammer AJ; Vo NT; Ledergerber B; Hermann F; Gämperli A; Huttner A; Evison J; Baumgartner I; Cavassini M; Hayoz D; Quitzau K; Hersberger M; Sudano I; Ruschitzka F; Lüscher TF; Noll G; Weber R
    Heart; 2009 Mar; 95(5):385-90. PubMed ID: 18653575
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
    Crutchley RD; Ma Q; Sulaiman A; Hochreitter J; Morse GD
    J Pharm Pract; 2011 Apr; 24(2):216-22. PubMed ID: 21712217
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anti-HIV agents. Atazanavir vs. Kaletra.
    TreatmentUpdate; 2005; 17(1):3-4. PubMed ID: 17225314
    [No Abstract]   [Full Text] [Related]  

  • 74. Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
    Furtek KJ; Crum NF; Olson PE; Wallace MR
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):394-6. PubMed ID: 16540945
    [No Abstract]   [Full Text] [Related]  

  • 75. Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
    Cahn PE; Gatell JM; Squires K; Percival LD; Piliero PJ; Sanne IA; Shelton S; Lazzarin A; Odeshoo L; Kelleher TD; Thiry A; Giordano MD; Schnittman SM
    J Int Assoc Physicians AIDS Care (Chic); 2004; 3(3):92-8. PubMed ID: 15573713
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Atazanavir: simplicity and convenience in different scenarios.
    Pérez-Elías MJ
    Expert Opin Pharmacother; 2007 Apr; 8(5):689-700. PubMed ID: 17376023
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
    Elion R; Berger D; Richmond G; Sension M; Dejesus E; Cimoch P; St Clair M; Yau L; Ha B;
    HIV Clin Trials; 2010; 11(3):170-3. PubMed ID: 20736153
    [No Abstract]   [Full Text] [Related]  

  • 78. Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).
    McKinnon JE; Mailliard RB; Swindells S; Wilkin TJ; Borowski L; Roper JM; Bastow B; Kearney M; Wiegand A; Mellors JW; Rinaldo CR;
    PLoS One; 2014; 9(5):e95524. PubMed ID: 24802242
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels.
    Hill A; Sawyer W; Gazzard B
    HIV Clin Trials; 2009; 10(1):1-12. PubMed ID: 19362991
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort.
    Cuzin L; Flandre P; Pugliese P; Duvivier C; Yazdanpanah Y; Billaud E; Poizot-Martin I; Katlama C;
    HIV Clin Trials; 2008; 9(3):147-51. PubMed ID: 18547901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.